Skip to Content
Merck
  • First gallamine-tacrine hybrid: design and characterization at cholinesterases and the M2 muscarinic receptor.

First gallamine-tacrine hybrid: design and characterization at cholinesterases and the M2 muscarinic receptor.

Journal of medicinal chemistry (2007-10-20)
Paul W Elsinghorst, Julia S Cieslik, Klaus Mohr, Christian Tränkle, Michael Gütschow
ABSTRACT

Gallamine and tacrine are allosteric antagonists at muscarinic M2 acetylcholine receptors and inhibitors of acetylcholinesterase. At both acetylcholine-binding proteins, gallamine and tacrine are known to occupy two different binding sites: in M2 receptors within the allosteric binding area and in acetylcholinesterase at its catalytic and its peripheral site. To find new ligands of both targets, we designed a gallamine-tacrine dimer and several derived hybrid compounds to address the two binding sites. Their M2 receptor allosteric and acetylcholinesterase inhibitory potential was determined. The hybrid compounds revealed an allosteric potency in the low nanomolar range exceeding the allosteric potency of gallamine and tacrine by factors of 100 and 4800, respectively. Cholinesterase inhibition was augmented by hybrid formation, and all compounds exhibited IC50 values in the lower nanomolar range. Thus, gallamine-tacrine hybrid formation is a valuable approach toward high affinity ligands concurrently targeting these acetylcholine-binding proteins.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Gallamine triethiodide, ≥98% (TLC), powder, muscarinic receptor antagonist